Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07739108

Suprainguinal Fascia Iliaca Block vs. Adductor Canal Block for Analgesia After Total Knee Arthroplasty

This study evaluates the analgesic efficacy and motor-sparing properties of ultrasound-guided Suprainguinal Fascia Iliaca Block (S-FIB) compared with Adductor Canal Block (ACB) in patients undergoing primary total knee arthroplasty (TKA). The main hypothesis is that ACB better preserves quadriceps muscle strength, allowing earlier functional mobilization, while providing comparable (non-inferior) analgesia to S-FIB.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Arthroplasty, Replacement, Knee

Age range

45 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Total knee arthroplasty is associated with severe postoperative pain requiring effective multimodal analgesia, and regional nerve blocks are integral to Fast-Track / ERAS (Enhanced Recovery After Surgery ) protocols. The Suprainguinal Fascia Iliaca Block (S-FIB) targets the anterior branches of the lumbar plexus (femoral, lateral femoral cutaneous, and obturator nerves) from a single high-volume injection, but proximal femoral spread can produce quadriceps motor weakness. The Adductor Canal Block (ACB) predominantly blocks the saphenous nerve, sparing motor function at the potential expense of less comprehensive analgesia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA Physical Status I, II, or III
  • Scheduled for elective unilateral primary total knee arthroplasty
  • Able to understand and operate the PCA device
  • Written informed consent provided

Exclusion criteria

  • Pre-existing lower-extremity neurological deficit or motor weakness (e.g., severe diabetic neuropathy)
  • Chronic opioid use (>30 mg oral morphine equivalents/day for >3 months)
  • Infection at the block site or systemic sepsis
  • Coagulopathy or bleeding diathesis
  • Allergy to local anesthetics or study medications
  • Revision TKA or bilateral knee procedures
  • Cognitive impairment or inability to perform mobility/pain assessments

Treatment and study plan

PCA

Drug

All patients receive standardized spinal anesthesia and postoperative intravenous PCA tramadol within a standardized multimodal regimen.

Primary outcomes

  1. Postoperative Pain Intensity (NRS)

    Time frame: Postoperative hours 24 hour

    Numerical Rating Scale (0-10) at rest and during active knee flexion (30°). Time Frame: Postoperative hours 2, 6, 12, 24, and 48.

Secondary outcomes

  1. Quadriceps Muscle Strength

    Time frame: Postoperative hours 6 and 12.

    Active Straight Leg Raise (SLR) Angle Maximum hip flexion angle (degrees, 0-90°) achieved during an active straight leg raise in the supine position, measured with a digital clinometer/goniometer.

  2. Cumulative Opioid Consumption

    Time frame: 24 and 48 hours postoperatively.

    Total IV tramadol delivered via PCA (patient controlled analgesia).

  3. Time to First Mobilization

    Time frame: Up to 48 hours postoperatively.

    Hours from end of surgery to first assisted/unassisted ambulation

  4. Quality of Recovery (QoR-15)

    Time frame: Baseline (preoperative) and 24 hours postoperatively.

    Validated 15-item questionnaire (0-150; higher = better recovery).

Study contacts

Contact information is provided by the study sponsor or research team.

Korgün Ökmen

CONTACT

[email protected]

+905057081021

Sponsors and collaborators

Lead sponsor

Bursa Yuksek Ihtisas Training and Research Hospital

Other Gov

Registry information

Official study title

Comparing Suprainguinal Fascia Iliaca Block Versus Adductor Canal Block for Postoperative Pain Control Following Total Knee Arthroplasty;A Prospective, Double-Blind Controlled Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.